Recombinant virus-like particle vaccine

This page covers all Recombinant virus-like particle vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Human papillomavirus types 6, 11, 16, and 18 (L1 capsid protein), HPV types 6, 11, 16, 18 (L1 major capsid protein), Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58.

Targets

Human papillomavirus types 6, 11, 16, and 18 (L1 capsid protein) · HPV types 6, 11, 16, 18 (L1 major capsid protein) · Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58

Marketed (2)

• Human papillomavirus quadrivalent vaccine · University of Alberta · Oncology / Immunology / Infectious Disease
  This vaccine stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV types 6, 11, 16, and 18) to prevent infection and associated diseases.
• quadrivalent HPV vaccine · International Agency for Research on Cancer · Oncology / Immunology
  The quadrivalent HPV vaccine stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV-6, 11, 16, and 18) to prevent infection and associated cancers.

Phase 3 pipeline (1)

• Gardasill 9™ vaccine · Imperial College London · Oncology / Immunology
  Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.